A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing

This registry study is observing how EndoPredict testing — a genomic test that analyzes breast cancer tumor tissue to predict the risk of the cancer spreading — influences treatment decisions and outcomes in early-stage breast cancer patients. Rather than testing a new treatment, this study collects real-world data about how the test is being used. **You may be eligible if...** - You are 18 years of age or older - You have invasive breast cancer (T1–T3 tumor size) - You have 0 to 3 positive lymph nodes - Your tumor tests positive for estrogen receptors (ER-positive) - Your tumor tests negative for HER2 - You have not yet received pre-operative chemotherapy **You may NOT be eligible if...** - You have had another primary cancer within the last 5 years (except treated non-melanoma skin cancer) - You received chemotherapy before your surgery - You have not signed the informed consent form Talk to your doctor to see if this trial is right for you.